Respiratory illness in Portugal
The three major respiratory pathogens side by side (influenza, COVID-19 and RSV) in Portugal, based on ECDC ERVISS weekly data from the Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA).
COVID-19: Moderate
Moderate
Yes, moderately. COVID activity in Portugal is currently moderate and holding steady (as of 16 Aug 2026).
Data window: Week 33 · Aug 10 – Aug 16 · Source: ECDC (weekly) · Source on seasonal break, next data from week 40
Get one free alert when the wave turns in Portugal
We write exactly once: the moment the level goes up. No account, no newsletter. We store your address and the country, nothing else. Every mail has a one click unsubscribe. Privacy
View the last 8 weeks
In week 33 of 2026, COVID-19 activity in Portugal is classified as moderate.
Against week 32 the reported value is effectively unchanged (less than 5% difference).
Across the last 8 reported weeks the highest reading was week 30; the level was moderate in 6 of them.
The last 8 reported weeks
| Week | Relative | Level | vs prior week |
|---|---|---|---|
| Week 33 | 95 | Moderate | unchanged |
| Week 32 | 97 | Moderate | unchanged |
| Week 31 | 96 | Moderate | unchanged |
| Week 30 | 100 | Moderate | – |
| Week 29 | 0 | Low | −100% |
| Week 28 | 86 | Moderate | −9% |
| Week 27 | 94 | Moderate | – |
| Week 26 | 0 | Low | – |
Relative means the highest of these weekly values is set to 100. Exact incidence rates are in the app.
Current activity
- InfluenzaLowstableWeek 33Trend: stable · Week 33
- COVID-19ModeratestableWeek 33Trend: stable · Week 33
- RSVLowstableWeek 33Trend: stable · Week 33
Situation by pathogen
Current activity in Portugal: Influenza low, COVID-19 moderate, RSV low. This reads the weekly ECDC publications, most recently Week 33.
InfluenzaDetails
In week 33 of 2026, activity of influenza (seasonal flu) in Portugal is low. The trend, derived from clinical surveillance, is stable.
COVID-19Details
In week 33 of 2026, activity of COVID-19 in Portugal is moderate. The trend, derived from clinical surveillance, is stable. Activity has barely shifted over the past few weeks.
RSVDetails
In week 33 of 2026, activity of respiratory syncytial virus (RSV) in Portugal is low. The trend, derived from clinical surveillance, is stable.
Data, context and methodology
The current picture for Portugal is built on the European Respiratory Virus Surveillance Summary (ERVISS), published weekly by the European Centre for Disease Prevention and Control (ECDC). the Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA) via the Médicos-Sentinela network is the national public-health authority that feeds ERVISS with sentinel primary care and virology data.
ECDC ERVISS
ERVISS is ECDC's weekly pan-European surveillance summary for influenza, SARS-CoV-2 and RSV. National authorities, in Portugal's case the Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA) via the Médicos-Sentinela network, submit harmonised indicators every week, which ECDC publishes in a standardised dataset on Thursdays. Using ERVISS rather than each country's native portal ensures cross-country comparability.
ILI / ARI consultation rates and positivity
the Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA) via the Médicos-Sentinela network operates a sentinel network of general practices that report weekly rates of patients consulting for influenza-like illness (ILI) or acute respiratory infection (ARI). A subset of patients is swabbed and tested by reference laboratories, producing pathogen-specific positivity rates for flu, SARS-CoV-2 and RSV.
Why this source
Combining consultation incidence with virological positivity yields a pathogen-specific weekly incidence signal (ILI × positivity / 100). This is the standard European methodology and provides a more robust view than either indicator alone: consultation rates capture illness burden, positivity confirms which pathogen is driving it.
Qualitative classification
The “low”, “moderate” and “high” categories follow seasonal reference values and epidemiological thresholds calibrated to match our classifications for other countries. The ILI × positivity / 100 product is scaled to comparable thresholds using a divisor of 3, which aligns European sentinel peaks with the consultation-equivalent scale used elsewhere. Data refreshes weekly when ECDC publishes the latest ERVISS update, typically on Thursdays.
Source and seasonal pattern by pathogen
- Influenza
- The classification is based on the ECDC ERVISS weekly reports, drawing on data from the Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA) via the Médicos-Sentinela network. Seasonally, infection waves in Portugal typically peak between December and February; activity is usually markedly lower during the summer months.
- COVID-19
- The classification is based on the ECDC ERVISS weekly reports, drawing on COVID-19 surveillance data from the Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA) via the Médicos-Sentinela network. Seasonally, infection waves in Portugal typically peak during winter, with occasional summer waves driven by new variants; activity is usually markedly lower in late spring between waves.
- RSV
- The classification is based on the ECDC ERVISS weekly reports, drawing on RSV surveillance data from the Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA) via the Médicos-Sentinela network. Seasonally, infection waves in Portugal typically peak between December and February; activity is usually markedly lower in spring and summer.
Frequently asked questions
How is overall respiratory-illness activity tracked in Portugal?
INSA combines sentinel GP consultations via Médicos Sentinela, sentinel-laboratory positivity, hospital and ICU admissions, wastewater detection of SARS-CoV-2, and variant characterisation by the National Reference Laboratory into a weekly respiratory-virus picture covering flu, SARS-CoV-2, and RSV. The same indicators feed ECDC ERVISS. On infectrisk.com we condense this picture into a qualitative low/moderate/high classification.
Did Portugal experience a “tripledemic”?
“Tripledemic” is a media term for the simultaneous winter circulation of flu, COVID-19, and RSV first widely discussed during the 2022–2023 season. Portugal saw clear co-circulation of all three pathogens that winter, with notable pressure on paediatric wards from RSV and on adult critical care from flu and COVID-19. Co-circulation has recurred each winter since, though the relative intensity of each pathogen varies.
Why do respiratory illnesses peak in a Portuguese winter?
The drivers are consistent across temperate Atlantic Europe, even in Portugal's milder climate. Many respiratory viruses remain stable longer in cool indoor air, and heated indoor environments reduce humidity in ways that weaken airway defence. People mix indoors more during Portuguese winters, schools amplify transmission among children, and end-of-year gatherings accelerate spread. Immunity to seasonal strains is also typically at its lowest as exposure rises.
How does INSA decide that activity is “high”?
INSA uses thresholds derived from historical reference data. Current indicators (sentinel consultations, laboratory positivity, hospitalisations, wastewater signals) are compared against baselines from past non-epidemic weeks and against reference points from severe past seasons. When several indicators cross into elevated ranges at the same time, the weekly bulletin flags activity as high. Portugal's ERVISS contribution uses the same framework for cross-country comparison.
How does Portugal compare to Spain and other EU countries?
Portugal's winter respiratory burden often tracks closely with Spain, reflecting similar climate, travel patterns, and demographic structure across the Iberian Peninsula. Because both report into ECDC ERVISS on the same schedule and methodology, the relative timing and intensity of their peaks is easy to read in the European dashboards. Lead–lag patterns between Portugal and its neighbours are usually small, driven more by school terms and travel than by climate.
More situation reports
Data last refreshed: Aug 31, 2026, 20:10. Update cadence: weekly.
This page is not medical advice and does not replace consultation with a healthcare professional. For specific symptoms, please contact a medical professional.
About this page
Published by Renderei Martin GmbH, Berlin. No commercial interest in individual health recommendations. The app is optionally monetised via a freemium subscription.
Content is based exclusively on the linked official surveillance publications. Medical statements are curated against the guidance of RKI, ECDC and WHO.
Methodology enquiries: press@infectrisk.com